Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.35 GBX | -2.90% | -1.47% | -21.18% |
Apr. 30 | EARNINGS AND TRADING: Software Circle & Beximco report higher revenue | AN |
Apr. 15 | Fusion Antibodies inks commercial contract for OptiPhage library | AN |
Business Summary
Number of employees: 48
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Recombinant Proteins and Antibodies
100.0
%
| 5 | 100.0 % | 3 | 100.0 % | -39.55% |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
North America
51.6
%
| 2 | 41.7 % | 1 | 51.6 % | -25.20% |
United Kingdom
21.4
%
| 1 | 15.1 % | 1 | 21.4 % | -14.23% |
Rest of Europe
14.1
%
| 1 | 29.0 % | 0 | 14.1 % | -70.66% |
Rest of World
12.9
%
| 1 | 14.2 % | 0 | 12.9 % | -44.93% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Adrian Kinkaid
CEO | Chief Executive Officer | 57 | 22-08-14 |
Stephen Smyth
DFI | Director of Finance/CFO | 49 | 23-08-23 |
Simon Douglas
CHM | Chairman | 65 | 05-12-31 |
Nicola Hamilton
COO | Chief Operating Officer | - | 16-05-31 |
Richard Buick
CTO | Chief Tech/Sci/R&D Officer | 47 | 01-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Colin Walsh
BRD | Director/Board Member | 68 | 06-12-31 |
Simon Douglas
CHM | Chairman | 65 | 05-12-31 |
Richard Buick
CTO | Chief Tech/Sci/R&D Officer | 47 | 01-12-31 |
Matthew Baker
BRD | Director/Board Member | 53 | 22-02-28 |
Adrian Kinkaid
CEO | Chief Executive Officer | 57 | 22-08-14 |
Sonya Ferguson
BRD | Director/Board Member | 53 | 15-12-31 |
Stephen Smyth
DFI | Director of Finance/CFO | 49 | 23-08-23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 95,365,564 | 85,480,210 ( 89.63 %) | 0 | 89.63 % |
Company contact information
Fusion Antibodies Plc
Springbank Industrial Estate 1 Springbank Road
BT17 0QL, Belfast
+44 28 9043 2800
http://www.fusionantibodies.comSector
Sales per region
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.52% | 4.18M | |
+41.79% | 54.04B | |
+46.23% | 41.96B | |
-0.56% | 41.92B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+29.60% | 12.28B | |
+24.91% | 12.19B |
- Stock Market
- Equities
- FAB Stock
- Company Fusion Antibodies plc